CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Teva Pharma Ind Adr Rep 1 - TEVA CFD

13.27
4.12%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Teva Pharmaceutical Industries Ltd ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 13.84
Open* 13.54
1-Year Change* 43.28%
Day's Range* 13.12 - 13.54
52 wk Range 7.09-11.64
Average Volume (10 days) 11.30M
Average Volume (3 months) 172.16M
Market Cap 12.37B
P/E Ratio -100.00K
Shares Outstanding 1.12B
Revenue 15.27B
EPS -1.98
Dividend (Yield %) N/A
Beta 1.00
Next Earnings Date Jan 31, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 12, 2024 13.27 -0.34 -2.50% 13.61 13.64 13.05
Apr 11, 2024 13.84 0.20 1.47% 13.64 13.96 13.64
Apr 10, 2024 13.82 0.00 0.00% 13.82 13.96 13.78
Apr 9, 2024 13.95 -0.14 -0.99% 14.09 14.09 13.73
Apr 8, 2024 14.18 -0.12 -0.84% 14.30 14.44 14.14
Apr 5, 2024 14.20 0.07 0.50% 14.13 14.30 13.93
Apr 4, 2024 13.90 -0.08 -0.57% 13.98 14.20 13.88
Apr 3, 2024 14.10 0.38 2.77% 13.72 14.14 13.72
Apr 2, 2024 13.84 0.05 0.36% 13.79 13.85 13.62
Apr 1, 2024 13.88 -0.27 -1.91% 14.15 14.16 13.84
Mar 28, 2024 14.08 -0.22 -1.54% 14.30 14.38 13.95
Mar 27, 2024 14.41 0.23 1.62% 14.18 14.42 14.14
Mar 26, 2024 14.12 0.07 0.50% 14.05 14.20 13.97
Mar 25, 2024 14.03 0.10 0.72% 13.93 14.14 13.84
Mar 22, 2024 13.87 0.16 1.17% 13.71 13.94 13.66
Mar 21, 2024 13.72 0.25 1.86% 13.47 13.77 13.44
Mar 20, 2024 13.46 0.19 1.43% 13.27 13.47 13.21
Mar 19, 2024 13.32 0.05 0.38% 13.27 13.39 13.14
Mar 18, 2024 13.29 -0.12 -0.89% 13.41 13.48 13.28
Mar 15, 2024 13.41 0.12 0.90% 13.29 13.62 13.29

Teva Pharma Ind Adr Rep 1 Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 14925 15878 16659 16887 18854
Revenue 14925 15878 16659 16887 18854
Cost of Revenue, Total 7487 8014 8870 9351 10558
Gross Profit 7438 7864 7789 7536 8296
Total Operating Expense 17024 14162 20231 17330 20537
Selling/General/Admin. Expenses, Total 3445 3402 3519 3667 4052
Research & Development 838 967 997 1010 1213
Unusual Expense (Income) 5239 1721 6739 3191 4838
Other Operating Expenses, Total 15 -41 -20 -28 -286
Operating Income -2099 1716 -3572 -443 -1683
Interest Income (Expense), Net Non-Operating -904 -988 -833 -825 -894
Other, Net -62 -70 -1 3 -19
Net Income Before Taxes -3065 658 -4406 -1265 -2596
Net Income After Taxes -2427 447 -4238 -987 -2304
Minority Interest 53 -39 109 2 322
Equity In Affiliates 21 9 138 -13 -71
Net Income Before Extra. Items -2353 417 -3991 -998 -2053
Total Extraordinary Items 0 0 -97
Net Income -2353 417 -3991 -998 -2150
Total Adjustments to Net Income 1 -1 -249
Income Available to Common Excl. Extra. Items -2353 417 -3990 -999 -2302
Income Available to Common Incl. Extra. Items -2353 417 -3990 -999 -2399
Dilution Adjustment
Diluted Net Income -2353 417 -3990 -999 -2399
Diluted Weighted Average Shares 1110 1107 1095 1091 1021
Diluted EPS Excluding Extraordinary Items -2.11982 0.37669 -3.64384 -0.91567 -2.25465
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS 0.94806 1.43282 0.35648 0.98547 0.82537
Depreciation / Amortization 99 126 139 162
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 3878 3661 3884 3595 3786
Revenue 3878 3661 3884 3595 3786
Cost of Revenue, Total 1959 2015 1784 1885 1958
Gross Profit 1919 1646 2100 1710 1828
Total Operating Expense 4524 3659 4739 3176 4735
Selling/General/Admin. Expenses, Total 910 842 837 777 849
Research & Development 240 234 210 175 228
Depreciation / Amortization 20 21
Unusual Expense (Income) 1448 571 1854 321 1683
Other Operating Expenses, Total -33 -3 54 -2 -4
Operating Income -646 2 -855 419 -949
Interest Income (Expense), Net Non-Operating -216 -260 -237 -230 -225
Other, Net -52 -9 -23 14
Net Income Before Taxes -914 -258 -1101 166 -1160
Net Income After Taxes -898 -239 -1255 59 -260
Minority Interest 35 33 32 -3 27
Equity In Affiliates 1 1 -1 0
Net Income Before Extra. Items -862 -206 -1222 55 -233
Net Income -862 -206 -1222 55 -233
Total Adjustments to Net Income -1 1 1 1 1
Income Available to Common Excl. Extra. Items -863 -205 -1221 56 -232
Income Available to Common Incl. Extra. Items -863 -205 -1221 56 -232
Diluted Net Income -863 -205 -1221 56 -232
Diluted Weighted Average Shares 1120 1115 1113 1119 1110
Diluted EPS Excluding Extraordinary Items -0.77054 -0.18386 -1.09704 0.05004 -0.20901
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.08375 0.16359 -0.01429 0.23651 0.77653
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 12051 12573 13005 13464 13794
Cash and Short Term Investments 2801 2165 2177 1975 1784
Cash & Equivalents 2801 2165 2177 1975 1782
Short Term Investments 2
Total Receivables, Net 3696 4529 4581 5676 5822
Accounts Receivable - Trade, Net 3696 4529 4581 5676 5822
Total Inventory 3833 3818 4403 4422 4731
Prepaid Expenses 1162 1075 945 870 899
Other Current Assets, Total 559 986 899 521 558
Total Assets 44006 47666 50640 57470 60683
Property/Plant/Equipment, Total - Net 6158 6477 6855 6950 6868
Property/Plant/Equipment, Total - Gross 11676 11718 11947 11864 11796
Accumulated Depreciation, Total -5518 -5241 -5092 -4914 -4928
Goodwill, Net 17633 20040 20624 24846 24917
Intangibles, Net 6270 7466 8923 11232 14005
Other Long Term Assets, Total 1894 1110 1233 978 1038
Total Current Liabilities 11469 11027 13164 13674 14322
Accounts Payable 1887 1686 1756 1718 1853
Accrued Expenses 2810 2880 2581 2680 2738
Notes Payable/Short Term Debt 23 23 514 514 516
Current Port. of LT Debt/Capital Leases 2086 1403 2674 1831 1700
Other Current Liabilities, Total 4663 5035 5639 6931 7515
Total Liabilities 36109 37388 40614 43498 45976
Total Long Term Debt 19103 21617 22731 24562 26691
Long Term Debt 19103 21617 22731 24562 26691
Deferred Income Tax 548 784 964 1096 2140
Minority Interest 794 966 1035 1091 1087
Other Liabilities, Total 4195 2994 2720 3075 1736
Total Equity 7897 10278 10026 13972 14707
Redeemable Preferred Stock 0
Common Stock 57 57 57 56 56
Additional Paid-In Capital 27688 27561 27443 27312 27210
Retained Earnings (Accumulated Deficit) -12882 -10529 -10946 -6956 -5958
Treasury Stock - Common -4128 -4128 -4128 -4128 -4142
Unrealized Gain (Loss) 0 0 0 1
Other Equity, Total -2838 -2683 -2400 -2312 -2460
Total Liabilities & Shareholders’ Equity 44006 47666 50640 57470 60683
Total Common Shares Outstanding 1110.9 1103.33 1096.51 1092.19 1089.39
Total Preferred Shares Outstanding 0 0 0
Long Term Investments 61
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 11425 12088 11501 12051 11453
Cash and Short Term Investments 2249 2669 2143 2801 2225
Cash & Equivalents 2249 2669 2143 2801 2225
Total Receivables, Net 3385 3539 3435 3696 3730
Accounts Receivable - Trade, Net 3385 3539 3435 3696 3730
Total Inventory 4051 4109 4118 3833 3859
Prepaid Expenses 1168 1228 1253 1162 1045
Other Current Assets, Total 572 543 552 559 594
Total Assets 42088 43095 43456 44006 44252
Property/Plant/Equipment, Total - Net 6028 6130 6171 6158 5990
Goodwill, Net 16885 17118 17799 17633 18433
Intangibles, Net 5525 5738 5964 6270 6393
Other Long Term Assets, Total 2225 2021 2021 1894 1983
Total Current Liabilities 11394 11843 10411 11469 11534
Accounts Payable 2280 2508 2381 1887 1635
Accrued Expenses 3271 2949 2699 2717 2537
Notes Payable/Short Term Debt 523 23 23 23 23
Current Port. of LT Debt/Capital Leases 956 1957 1000 2086 2746
Other Current Liabilities, Total 4364 4406 4308 4756 4593
Total Liabilities 35158 36043 35595 36109 35484
Total Long Term Debt 18495 18698 19668 19103 18497
Long Term Debt 18495 18698 19668 19103 18497
Deferred Income Tax 544 534 550 548 503
Minority Interest 582 656 751 794 751
Other Liabilities, Total 4143 4312 4215 4195 4199
Total Equity 6930 7052 7861 7897 8768
Common Stock 57 57 57 57 57
Additional Paid-In Capital 27780 27748 27719 27688 27652
Retained Earnings (Accumulated Deficit) -13870 -13950 -13086 -12882 -11660
Treasury Stock - Common -4128 -4128 -4128 -4128 -4128
Other Equity, Total -2909 -2675 -2701 -2838 -3153
Total Liabilities & Shareholders’ Equity 42088 43095 43456 44006 44252
Total Common Shares Outstanding 1120.97 1120.65 1120.41 1110.9 1110.64
Total Preferred Shares Outstanding
Unrealized Gain (Loss)
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -2406 456 -4099 -1000 -2472
Cash From Operating Activities 1590 798 1216 748 2446
Cash From Operating Activities 1308 1330 1557 1722 1842
Deferred Taxes -1059 -120 -696 -985 -837
Non-Cash Items 2490 833 6642 1907 5736
Cash Taxes Paid 543 495 709 552 420
Cash Interest Paid 948 913 846 840 815
Changes in Working Capital 1257 -1701 -2188 -896 -1823
Cash From Investing Activities 656 1523 863 1355 1866
Capital Expenditures -548 -562 -578 -525 -651
Other Investing Cash Flow Items, Total 1204 2085 1441 1880 2517
Cash From Financing Activities -1487 -2172 -1885 -1926 -3351
Financing Cash Flow Items -118 -6 -5 -11 -57
Total Cash Dividends Paid 0 0 -52 -22
Issuance (Retirement) of Stock, Net 0
Issuance (Retirement) of Debt, Net -1369 -2166 -1880 -1863 -3272
Foreign Exchange Effects -123 -128 8 16 -142
Net Change in Cash 636 21 202 193 819
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -238 -2406 -1152 -1211 -952
Cash From Operating Activities -145 1590 617 73 -49
Cash From Operating Activities 304 1308 1002 681 323
Deferred Taxes -106 -1059 -1214 -1258 -175
Non-Cash Items 259 2490 974 949 196
Changes in Working Capital -364 1257 1007 912 559
Cash From Investing Activities 181 656 488 341 161
Capital Expenditures -139 -548 -406 -284 -157
Other Investing Cash Flow Items, Total 320 1204 894 625 318
Cash From Financing Activities -706 -1487 -776 -336 2
Financing Cash Flow Items -5 -118 -115 -40 2
Issuance (Retirement) of Debt, Net -701 -1369 -661 -296 0
Foreign Exchange Effects 12 -123 -269 -185 -62
Net Change in Cash -658 636 60 -107 52
Total Cash Dividends Paid

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Teva Company profile

Teva Pharmaceutical (TEVA) is a multinational pharmaceutical company set up in Jerusalem in 1901. The business’s primary focus is generic drugs. Teva is a world leader in specialty medicines. Teva production facilities are based in Israel, North America, South America and Europe. Their generic drugs portfolio includes over 1,000 products that represent therapeutic versions of innovative drugs. Their specialty medicines portfolio features a wide scope of treatments of the CNS disorders. The company’s shares are traded on the New York Stock Exchange (NYSE) and on the Tel Aviv Stock Exchange (TASE). To stay informed on the latest Teva Pharma share price, follow Capital.com.
Industry: Pharmaceuticals (NEC)

5 Bazel St
P O B 3190
PETAH TIKVA
49131
IL

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

Gold

2,355.21 Price
+0.510% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.50

XRP/USD

0.50 Price
+15.560% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,126.43 Price
+7.260% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

18,039.80 Price
+0.220% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading